Pharmaceutical co-crystals: A novel strategy for improving drug solubility and bioavailability

Read full text Summarise with VIRAT
Authors: D Umamaheswari, R. Senthil Prabhu, Shree Aashika M, Shree Aashika M, Shri Shankari R
Cited by: 0
References: 28

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Poor aqueous solubility and low bioavailability remain major challenges in the development of solid oral dosage forms, particularly for BCS Class II and IV drugs. Pharmaceutical co-crystals have emerged as an effective solid-state modification strategy to enhance physicochemical and biopharmaceutical properties of active pharmaceutical ingredients without altering their chemical structure or pharmacological activity. Co-crystals are multicomponent crystalline systems formed through non-covalent interactions between an API and a pharmaceutically acceptable co-former, enabling controlled modulation of solubility, dissolution rate, stability, permeability, and mechanical properties. This review summarizes the fundamentals of pharmaceutical co-crystals, their distinction from other solid-state forms, and key preparation techniques. The impact of co-crystallization on critical properties, including solubility, dissolution, bioavailability, stability, and tabletability, is discussed along with major pharmaceutical applications. Despite notable advances, challenges related to co-former selection, scalability, stability, and regulatory considerations remain. Overall, pharmaceutical co-crystals represent a promising platform for improving drug performance and advancing modern formulation development.

Fields of Study & Subjects

Crystallization and Solubility Studies Drug Solubulity and Delivery Systems Crystallography and molecular interactions

Publication details

Journal / source
International Journal of Pharmacy and Pharmaceutical Science
Volume
8
Issue
2
Pages
64–72
Publication date
1 February 2026
Language
EN